Rapport Therapeutics, Inc. Common Stock (RAPP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.55B
Last updated: Nov 17, 2026 at 11:05 AM ET
Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Forecast
Analysts expect Rapport Therapeutics, Inc. Common Stock (RAPP) to earn -$3.29 per share in the fiscal year ending Dec 31, 2026, on revenue of $20.01M. Of 16 analysts, 16 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$4.02.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 1.94, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 6.3% |
| Buy | 15 | 93.8% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 16
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$3.29
- EPS consensus, revenue $20.01M
- Fiscal year ending Dec 31, 2027
- -$4.02
- EPS consensus
- Next report
- Mar 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.29 | -$3.91 to -$2.73 | 11 | $20.01M | $20.00M to $20.10M | 15 |
| Dec 31, 2027 | -$4.02 | -$4.99 to -$3.22 | 12 | N/A | N/A | 14 |
Quarterly Estimates
The EPS consensus rises from -$1.03 for the quarter ending Dec 31, 2026 to -$0.93 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.03 | -$1.51 to -$0.84 | 18 | $7283 | N/A | 17 |
| Mar 31, 2027 | -$0.93 | -$1.20 to -$0.78 | 7 | N/A | N/A | 8 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$4.09.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.29 | -$3.64 | -$4.09 | -$4.09 | -$4.09 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.02 | -$4.47 | -$5.09 | -$5.23 | -$5.23 | N/A |
| Quarter ending Mar 31, 2027 | -$0.93 | -$1.09 | -$1.27 | -$1.33 | -$1.33 | N/A |
Frequently Asked Questions About RAPP
What is the RAPP stock forecast?
Consensus analyst estimates put Rapport Therapeutics, Inc. Common Stock's EPS at -$3.29 for the fiscal year ending Dec 31, 2026, on revenue of $20.01M. The consensus rating from 16 analysts is Buy.
How do analysts rate RAPP stock?
Of 16 analysts covering Rapport Therapeutics, Inc. Common Stock, 1 rates it Strong Buy, 15 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RAPP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.29, with estimates from -$3.91 to -$2.73 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.02, with estimates from -$4.99 to -$3.22 from 12 analysts.
What revenue do analysts expect from Rapport Therapeutics, Inc. Common Stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $20.01M, with estimates from $20.00M to $20.10M.
How many analysts cover RAPP?
16 analysts rate Rapport Therapeutics, Inc. Common Stock stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RAPP pages: Overview, Earnings, Forecast, Competitors